Although paclitaxel enhanced TIMP-1 expression on parental OVCAR4 cells, Momelotinib had no effect on its expression, strongly suggesting that TIMP-2 mediated chemotherapy-induced STAT3 activation is essential for chemoresistant and CSC phenotypes in ovarian cancer. Here, TIMP1 is linked to ovarian cancer.